Wuhan Thalys Med Tech Co Ltd (603716) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Wuhan Thalys Med Tech Co Ltd stock ¥12.05, price ¥14.28, that is 15.6% below the price, quality 37 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Wuhan Thalys Med Tech Co Ltd
603716 · SHGExpensive (fair value 16% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range ¥5.26 – ¥36.40 · fair‑value band ¥9.04 – ¥15.07 · the ¥14.28 price screens above the ¥12.05 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Wuhan Thalys Med Tech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. It offers automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products.
Show moreShow less
The company also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis system; automated chemiluminescence immunoassay system; and blood analyzer.
The company was formerly known as Thalys Medical Technology Inc. and changed its name to Thalys Medical Technology Group Inc. in September 2020. Thalys Medical Technology Group Inc. was founded in 2004 and is headquartered in Wuhan, China.
Stock analysis
Wuhan Thalys Med Tech Co Ltd (603716) currently trades at ¥14.28, while our estimate is ¥12.05, 16% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: ¥9.04 (bear) to ¥15.07 (bull), the price of ¥14.28 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Wuhan Thalys Med Tech Co Ltd reported revenue of 1.1B CNY in FY2025 versus 2.6B CNY in FY2021, a compound −19.8%/yr. Reported net income was −207M CNY in FY2025.
Key figures
Market cap 3.1B CNY (≈ $469M) Small · P/S ratio 5.12 · EPS (TTM) ¥−0.9700 · Dividend yield 0.5% · Net margin −24.8% · Return on equity −17.6% · Return on assets (EBIT) −3.6% (5-year average) · Operating margin −2.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (medium confidence).
What moves the price
The share trades about 51% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −16%, 603716 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Wuhan Thalys Med Tech Co Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 151 stocks
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- Stock screener with 62 metrics
- Undervalued stocks: Chinese Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| IQVIA Holdings IQV | $257.60 | $291.63 | +13% | vs 603716 |
| WuXi AppTec Co 603259 | ¥146.07 | ¥164.66 | +13% | vs 603716 |
| Illumina, Inc ILMN | $202.61 | $227.71 | +12% | vs 603716 |
| Thermo Fisher Scientific Inc TMO | $686.79 | $686.04 | +0% | vs 603716 |
| Danaher Corporation DHR | $225.77 | $209.18 | −7% | vs 603716 |
| IDEXX Laboratories, Inc IDXX | $690.24 | $496.48 | −28% | vs 603716 |
| Lonza Group LONN | CHF 663.00 | CHF 259.80 | −61% | vs 603716 |
| Mettler-Toledo International Inc MTD | $1,713 | $655.06 | −62% | vs 603716 |
| Agilent Technologies, Inc A | $172.22 | $64.20 | −63% | vs 603716 |
| Waters Corporation WAT | $449.78 | $91.26 | −80% | vs 603716 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Wuhan Thalys Med Tech Co Ltd (603716) overvalued or undervalued?
What is the fair value of 603716?
What is the quality score of 603716?
What is the price target for Wuhan Thalys Med Tech Co Ltd (603716)?
What is the Wuhan Thalys Med Tech Co Ltd stock forecast for 2026?
What is the revenue of Wuhan Thalys Med Tech Co Ltd (603716)?
Does Wuhan Thalys Med Tech Co Ltd pay a dividend?
How much is the dividend of Wuhan Thalys Med Tech Co Ltd (603716)?
What is the intrinsic value of Wuhan Thalys Med Tech Co Ltd (603716)?
Is Wuhan Thalys Med Tech Co Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 603716?
How much is Wuhan Thalys Med Tech Co Ltd worth?
What do the bullish and bearish scenarios say about 603716?
How solid is the balance sheet of Wuhan Thalys Med Tech Co Ltd (603716)?
How far is 603716 from its 52-week high?
Which stocks are comparable to Wuhan Thalys Med Tech Co Ltd?
Is Wuhan Thalys Med Tech Co Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Wuhan Thalys Med Tech Co Ltd (603716)?
What should I pay attention to with Wuhan Thalys Med Tech Co Ltd right now?
Key figures of Wuhan Thalys Med Tech Co Ltd
How large is the market capitalisation of Wuhan Thalys Med Tech Co Ltd (603716)?
What is the P/S ratio of Wuhan Thalys Med Tech Co Ltd (603716)?
What are the earnings per share of Wuhan Thalys Med Tech Co Ltd (603716)?
What is the dividend yield of Wuhan Thalys Med Tech Co Ltd (603716)?
What is the net margin of Wuhan Thalys Med Tech Co Ltd (603716)?
What is the return on equity of Wuhan Thalys Med Tech Co Ltd (603716)?
What is the EBIT return on assets of Wuhan Thalys Med Tech Co Ltd (603716)?
What is the operating margin of Wuhan Thalys Med Tech Co Ltd (603716)?
How fast is revenue growing at Wuhan Thalys Med Tech Co Ltd (603716)?
How fast are earnings growing at Wuhan Thalys Med Tech Co Ltd (603716)?
How much free cash flow does Wuhan Thalys Med Tech Co Ltd (603716) generate?
How much net debt does Wuhan Thalys Med Tech Co Ltd (603716) carry?
Watch Wuhan Thalys Med Tech Co Ltd in the live analysis
One click puts Wuhan Thalys Med Tech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.